Cargando…

PCI-24781, a Novel Hydroxamic Acid HDAC Inhibitor, Exerts Cytotoxicity and Histone Alterations via Caspase-8 and FADD in Leukemia Cells

Histone deacetylase inhibitors (HDACi) have become a promising new avenue for cancer therapy, and many are currently in Phase I/II clinical trials for various tumor types. In the present study, we show that apoptosis induction and histone alterations by PCI-24781, a novel hydroxamic acid-based HDAC...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rivera-Del Valle, Nilsa, Gao, Shan, Miller, Claudia P., Fulbright, Joy, Gonzales, Carolina, Sirisawad, Mint, Steggerda, Susanne, Wheler, Jennifer, Balasubramanian, Sriram, Chandra, Joya
Formato:	Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2010
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2817379/ https://www.ncbi.nlm.nih.gov/pubmed/20145726 http://dx.doi.org/10.1155/2010/207420

Ejemplares similares

The histone deacetylase inhibitor PCI-24781 as a putative radiosensitizer in pediatric glioblastoma cell lines
por: de Andrade, Pamela Viani, et al.
Publicado: (2016)

The histone deacetylase inhibitor PCI-24781 impairs calcium influx and inhibits proliferation and metastasis in breast cancer
por: Yang, Tianshu, et al.
Publicado: (2021)

RuvBL2 Is Involved in Histone Deacetylase Inhibitor PCI-24781-Induced Cell Death in SK-N-DZ Neuroblastoma Cells
por: Zhan, Qinglei, et al.
Publicado: (2013)

PCI-24781 down-regulates EZH2 expression and then promotes glioma apoptosis by suppressing the PIK3K/Akt/mTOR pathway
por: Zhang, Wei, et al.
Publicado: (2014)

DED Interaction of FADD and Caspase-8 in the Induction of Apoptotic Cell Death
por: Park, Young-Hoon, et al.
Publicado: (2022)

Caspase-8 and FADD prevent spontaneous ZBP1 expression and necroptosis
por: Rodriguez, Diego A., et al.
Publicado: (2022)

Synthesis and HDAC inhibitory activity of pyrimidine-based hydroxamic acids
por: Jakubkiene, Virginija, et al.
Publicado: (2022)

Hydroxamic acid derivatives as HDAC1, HDAC6 and HDAC8 inhibitors with antiproliferative activity in cancer cell lines
por: Sixto-López, Yudibeth, et al.
Publicado: (2020)

Molecular docking and ADMET analysis of hydroxamic acids as HDAC2 inhibitors
por: Alsawalha, Murad, et al.
Publicado: (2019)

Hydroxamic Acids Immobilized on Resins (HAIRs): Synthesis of Dual‐Targeting HDAC Inhibitors and HDAC Degraders (PROTACs)
por: Sinatra, Laura, et al.
Publicado: (2020)

A Rational Approach for the Identification of Non-Hydroxamate HDAC6-Selective Inhibitors
por: Goracci, Laura, et al.
Publicado: (2016)

Tests on PIDC to determine magnetic field interference (24.7.81-27.7.81)
por: Unser, K
Publicado: (1981)

The adaptor protein FADD and the initiator caspase-8 mediate activation of NF-κB by TRAIL
por: Grunert, M, et al.
Publicado: (2012)

Loss of FADD and Caspases Affects the Response of T-Cell Leukemia Jurkat Cells to Anti-Cancer Drugs
por: Mrkvová, Zuzana, et al.
Publicado: (2021)

FADD adaptor in cancer
por: Tourneur, Léa, et al.
Publicado: (2005)

NFκB activation by Fas is mediated through FADD, caspase-8, and RIP and is inhibited by FLIP
por: Kreuz, Sebastian, et al.
Publicado: (2004)

A novel small molecule hydroxamate preferentially inhibits HDAC6 activity and tumour growth
por: Kaliszczak, M, et al.
Publicado: (2013)

In silico modification of suberoylanilide hydroxamic acid (SAHA) as potential inhibitor for class II histone deacetylase (HDAC)
por: Tambunan, Usman SF, et al.
Publicado: (2011)

LBH589, A Hydroxamic Acid-Derived HDAC Inhibitor, is Neuroprotective in Mouse Models of Huntington’s Disease
por: Chopra, Vanita, et al.
Publicado: (2016)

FADD the bad in head and neck cancer
por: Dent, Paul
Publicado: (2013)

Hydroxamic Acid-Based Histone Deacetylase (HDAC) Inhibitors Bearing a Pyrazole Scaffold and a Cinnamoyl Linker
por: Zagni, Chiara, et al.
Publicado: (2019)

Design of Fluorescent Coumarin-Hydroxamic Acid Derivatives as Inhibitors of HDACs: Synthesis, Anti-Proliferative Evaluation and Docking Studies
por: García, Santiago, et al.
Publicado: (2020)

Hydroxamic Acid-Modified Peptide Library Provides Insights into the Molecular Basis for the Substrate Selectivity of HDAC Corepressor Complexes
por: Archibald, Lewis J., et al.
Publicado: (2022)

Design, Synthesis and Biological Evaluation of Novel Coumarin-Based Hydroxamate Derivatives as Histone Deacetylase (Hdac) Inhibitors with Antitumor Activities
por: Yang, Feifei, et al.
Publicado: (2019)

Crystal structure of FadD32, an enzyme essential for mycolic acid biosynthesis in mycobacteria
por: Li, Wenjuan, et al.
Publicado: (2015)

FADD is a key regulator of lipid metabolism
por: Zhuang, Hongqin, et al.
Publicado: (2016)

Cryo-EM structural analysis of FADD:Caspase-8 complexes defines the catalytic dimer architecture for co-ordinated control of cell fate
por: Fox, Joanna L., et al.
Publicado: (2021)

Molecular and cellular effects of a novel hydroxamate-based HDAC inhibitor – belinostat – in glioblastoma cell lines: a preliminary report
por: Kusaczuk, Magdalena, et al.
Publicado: (2016)

Interaction of Imidazole Containing Hydroxamic Acids with Fe(III): Hydroxamate Versus Imidazole Coordination of the Ligands
por: Farkas, Etelka, et al.
Publicado: (2007)

Deregulated FADD expression and phosphorylation in T-cell lymphoblastic lymphoma
por: Marín-Rubio, José L., et al.
Publicado: (2016)

FADD as a key molecular player in cancer progression
por: Liu, Ying, et al.
Publicado: (2022)

Adjuvant Epigenetic Therapy of Decitabine and Suberoylanilide Hydroxamic Acid Exerts Anti-Neoplastic Effects in Acute Myeloid Leukemia Cells
por: Abou Najem, Sonia, et al.
Publicado: (2019)

Oxazole-Bridged Combretastatin A-4 Derivatives with Tethered Hydroxamic Acids: Structure–Activity Relations of New Inhibitors of HDAC and/or Tubulin Function
por: Schmitt, Florian, et al.
Publicado: (2019)

Novel hydroxamates potentiated in vitro activity of fluconazole against Candida albicans
por: Paul-Satyaseela, Maneesh, et al.
Publicado: (2017)

Either fadD1 or fadD2, Which Encode acyl-CoA Synthetase, Is Essential for the Survival of Haemophilus parasuis SC096
por: Feng, Saixiang, et al.
Publicado: (2017)

Molecular design, synthesis and in vitro biological evaluation of thienopyrimidine–hydroxamic acids as chimeric kinase HDAC inhibitors: a challenging approach to combat cancer
por: Abdel-Atty, Mona M., et al.
Publicado: (2021)

Metabolism, HDACs, and HDAC Inhibitors: A Systems Biology Perspective
por: King, Jacob, et al.
Publicado: (2021)

Functional complementation between FADD and RIP1 in embryos and lymphocytes
por: Zhang, Haibing, et al.
Publicado: (2011)

FADD in Cancer: Mechanisms of Altered Expression and Function, and Clinical Implications
por: Marín-Rubio, José L, et al.
Publicado: (2019)

A Dual Role for FADD in Human Precursor T-Cell Neoplasms
por: Marín-Rubio, José Luis, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ol61c6ivr5cauu7a40ijfn37s0